Pfizer (PFE) Long-Term Investments (2009 - 2026)

Pfizer (PFE) has reported Long-Term Investments for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments fell 19.27% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (down 19.27% YoY), while the FY2025 annual figure was $1.6 billion, down 27.24% from the prior year.
• Long-Term Investments was little changed at $1.6 billion in Q1 2026 per PFE's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Long-Term Investments topped out at $19.0 billion in Q3 2022 and bottomed at $1.6 billion in Q4 2025.
• Historically, Long-Term Investments has averaged $6.8 billion across 5 years, with a median of $4.7 billion in 2022.
• Annual changes were most pronounced in 2022 — Long-Term Investments surged 337.52% — and 2024, when it tumbled 85.5%.
• Pfizer's Long-Term Investments stood at $10.8 billion in 2022, then surged by 41.98% to $15.4 billion in 2023, then sank by 85.5% to $2.2 billion in 2024, then dropped by 27.24% to $1.6 billion in 2025, then climbed by 0.31% to $1.6 billion in 2026.
• Business Quant data shows PFE's Long-Term Investments at $1.6 billion in Q1 2026, $1.6 billion in Q4 2025, and $2.1 billion in Q3 2025.